Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
20
06
2021
pubmed:
10
7
2021
medline:
28
1
2022
entrez:
9
7
2021
Statut:
ppublish
Résumé
Dasatinib, an orally administered Src-family kinase inhibitor, is combined with the standard chemotherapeutic regimen to enhance antineoplastic activity against core-binding factor acute myeloid leukemia (CBF-AML) in adults; however, limited data are available for use in children. In the present study, we studied the pharmacokinetics and safety of dasatinib in children. Dasatinib (60 or 80 mg/m Twenty pediatric patients (3.3-14.4 years of age) were included, and a total of 40 dasatinib concentrations were available for population pharmacokinetic analysis. The mean (standard deviation) of the estimated area under the concentration-time curve extrapolated to steady state (AUC The population pharmacokinetics of orally administered dasatinib were evaluated in pediatric CBF-AML patients. The AUC
Sections du résumé
BACKGROUND
Dasatinib, an orally administered Src-family kinase inhibitor, is combined with the standard chemotherapeutic regimen to enhance antineoplastic activity against core-binding factor acute myeloid leukemia (CBF-AML) in adults; however, limited data are available for use in children. In the present study, we studied the pharmacokinetics and safety of dasatinib in children.
METHODS
Dasatinib (60 or 80 mg/m
RESULTS
Twenty pediatric patients (3.3-14.4 years of age) were included, and a total of 40 dasatinib concentrations were available for population pharmacokinetic analysis. The mean (standard deviation) of the estimated area under the concentration-time curve extrapolated to steady state (AUC
CONCLUSIONS
The population pharmacokinetics of orally administered dasatinib were evaluated in pediatric CBF-AML patients. The AUC
Identifiants
pubmed: 34240339
doi: 10.1007/s40262-021-01054-6
pii: 10.1007/s40262-021-01054-6
doi:
Substances chimiques
Core Binding Factors
0
Protein Kinase Inhibitors
0
Dasatinib
RBZ1571X5H
Banques de données
ClinicalTrials.gov
['NCT03844360']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-81Subventions
Organisme : National Nature Science Foundation of China
ID : 81670112
Organisme : National Nature Science Foundation of China
ID : 81770175
Organisme : National Nature Science Foundation of China
ID : 81890992
Organisme : National Nature Science Foundation of China
ID : 8190011827
Organisme : National Science and Technology Major Project
ID : 2017ZX09304029-002
Organisme : Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
ID : 2018RC310019
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Song TY, Lee SH, Kim G, Baek HJ, Hwang TJ, Kook H. Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. Blood Res. 2018;53(1):25–34.
doi: 10.5045/br.2018.53.1.25
Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer. 2014;120(16):2497–506.
doi: 10.1002/cncr.28748
Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965–70.
doi: 10.1038/sj.leu.2404188
Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, Loken MR, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res. 2019;25(16):5038–48.
doi: 10.1158/1078-0432.CCR-18-1897
Tokumasu M, Murata C, Shimada A, Ohki K, Hayashi Y, Saito AM, et al. Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Leukemia. 2015;29(12):2438–41.
doi: 10.1038/leu.2015.121
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322–33.
Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015;33(36):4247–58.
doi: 10.1200/JCO.2015.61.1947
Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15(3):348–54.
doi: 10.1038/sj.leu.2402046
Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56–62.
doi: 10.1182/blood.V97.1.56
Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. Ann Hematol. 2004;83(Suppl 1):S108–12.
pubmed: 15124698
Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol. 2002;20(12):2774-82.
Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19(9):1536–42.
doi: 10.1038/sj.leu.2403870
Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003;102(4):1474–9.
doi: 10.1182/blood-2003-01-0137
Cairoli R, Grillo G, Beghini A, Tedeschi A, Ripamonti CB, Larizza L, et al. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia. 2003;17(2):471–2.
doi: 10.1038/sj.leu.2402795
Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473–81.
doi: 10.1158/0008-5472.CAN-05-2050
Leveque D, Becker G, Bilger K, Natarajan-Ame S. Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet. 2020;59(7):849–56.
doi: 10.1007/s40262-020-00872-4
Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11–08 trial. Leukemia. 2018;32(7):1621–30.
doi: 10.1038/s41375-018-0129-6
Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31(19):2460–8.
doi: 10.1200/JCO.2012.46.8280
Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187–97.
doi: 10.1007/s11095-007-9361-x
Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed. 2008;90(2):154–66.
doi: 10.1016/j.cmpb.2007.12.002
Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;3(2):e51.
doi: 10.1038/psp.2013.26
Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107(5):1806–9.
doi: 10.1182/blood-2005-08-3408
Manara E, Bisio V, Masetti R, Beqiri V, Rondelli R, Menna G, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia. 2014;28(5):1132–4.
doi: 10.1038/leu.2013.339
Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463–8.
doi: 10.1182/blood-2005-09-3640
Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791–9.
doi: 10.1182/blood-2005-04-1466
Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27(9):1891–901.
doi: 10.1038/leu.2013.186
Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121(1):170–7.
doi: 10.1182/blood-2012-05-431486
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.
doi: 10.1200/JCO.2015.64.8899
Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children’s oncology group phase I consortium. J Clin Oncol. 2011;29(7):839–44.
doi: 10.1200/JCO.2010.30.7231
Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, et al. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma. 2018;59(11):2595–601.
doi: 10.1080/10428194.2018.1443330